S1: Financial and operational highlights:
– Total net product revenue achieved in Q1 2025 was $612 million, a 70% growth over the same quarter last year.
– PMO franchise revenue grew 5% to $237 million for the quarter.
– Elevitus achieved a sales figure of $375 million for the quarter, representing a 180% increase.
– Cash position reported at the end of the quarter was $647 million, with an additional $600 million available through a revolving credit facility.
– R&D expenses on a GAAP basis was $773 million, mainly due to a $584 million R&D expense linked to the Arrowhead collaboration.
– SG&A expenses increased by 5% year over year to $134 million.
S2: Market Expansion
The company has identified a need to focus on secondary treatment sites with available capacity to balance the distribution and address demand adequately. Despite challenges, they are seeing interest from both ambulant and non-ambulant patients in enrolling for the treatment.
S3: Strategic Cooperation
The company has reaffirmed that all agreements with Roche remain intact, reporting revenues from collaboration credits associated with Roche’s expired option on a certain program. Additionally, Sarepta is working with the FDA under existing regulatory pathways for approvals, keeping strategic cooperation within regulatory compliance.
S4: New Product Launch
The launch of Elevitus is recognized as the most successful in vivo gene therapy launch to date, using market insights and educational outreach to bolster its uptake. The company has also observed successful results in its LGMD type IIe program, expecting a BLA submission in the second half of the year.
S5: Management Change
There have been no management changes reported during this earnings call.
S6: Next quarter forward looking estimates by management team
For the full year 2025, the revised net product revenue guidance is between $2.3 billion to $2.6 billion. This reduction reflects updated assumptions based on recent administrative issues and the need to expand education and site capacity beyond the top treatment sites. The fundamentals related to the therapy’s opportunity remain unchanged, with the expectation that Q2 revenue could be up to 20% lower than Q1, but there’s optimism for a demand uptick from the summer, extending through the remainder of the year.